Adults with moderate to severely active rheumatoid arthritis that are receiving first-time therapy with bDMARDs or tsDMARDS. Appropriate comparator therapy: bDMARDs or tsDMARDs (abatacept, or adalimumab, or baricitinib, or certolzumab-pegol, or etanercept, or golimumab, or infliximab, or sarilumab, or tocilizumab, or upadacitinib) in combination with MTX, or as monotherapy, depending on tolerance or suitability to MTX.

Adults with moderate to severely active rheumatoid arthritis who have received previous treatment with one or more bDMARDs and/or tsDMARDs, and have not responded or tolerated. Appropriate comparator therapy: Change of bDMARD or tsDMARD therapy (abatacept, or adalimumab, or baricitinib, or certolizumab-pegol, or etanercept, or golimumab, or infliximab, or sarilumab, or tocilizumab, or upadacitinib in combination with MTX, or as monotherapy, depending on tolerance or suitability to MTX; or in patients with severe rheumatoid arthritis taking rituximab) in dependence of previous therapy.